Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment

Blood

Volumn 100, Issue 3, 2002, Pages 1014-1018

  Roche Lestienne, Catherine ^a,b   Soenen Cornu, Valerie ^a,b   Grardel Duflos, Nathalie ^a,b   Laï, Jean Luc ^a,b   Philippe, Nathalie ^a,b   Facon, Thierry ^a,b   Fenaux, Pierre ^a,b   Preudhomme, Claude ^a,b  

^a INSERM   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; PROTEIN TYROSINE KINASE;

ADULT; AGED; ARTICLE; CANCER STAGING; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CRYSTALLOGRAPHY; ENZYME ACTIVITY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENE TARGETING; HUMAN; MALE; OLIGONUCLEOTIDE PROBE; POINT MUTATION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0036682481     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V100.3.1014     Document Type: Article

References (20)

1. The molecular genetics of Philadelphia chromosome-positive leukemias
2. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype
3. In vitro transformation of immature hematopoietic cells by the p210 BCR-ABL oncogene product of the Philadelphia chromosome
4. Induction of chronic myelogenous leukemia in mice by the p210 BCR-ABL gene of the Philadelphia chromosome
5. Chronic myeloid leukemia
6. Effects of a selective inhibitor of the ABL tyrosine kinase on the growth of BCR-ABL positive cells
7. Inhibition of the Abl protein tyrosine kinase in vivo and in vitro by a 2-phenylaminopyrimidine derivative
8. Inhibition of the Abl kinase activity blocks the proliferation of BCR/ABL + leukemia cells and induces apoptosis
9. Roots of clinical resistance to STI571 cancer therapy
10. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
11. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
12. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification
13. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines
14. Selection and characterization of BCR-ABL-positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanism of resistance
15. Clinical resistance to STI571 cancer therapy caused by BCR-ABL gene mutation or amplification
16. Roots of clinical resistance to STI571 cancer therapy
17. Roots of clinical resistance to STI571 cancer therapy
18. Structural mechanism for STI571 inhibition of Abelson tyrosine kinase
19. Evaluation of minimal residual disease using reverse transcription polymerase chain reaction in t(8;21) acute myeloid leukemia: A multicenter study of 51 patients
20. Point mutations clustered within the ATP binding region of BCR-ABL are common in patients with emerging Glivec resistance but not in Glivecresponsive cases of CML